📊 NPCE Key Takeaways
Is NPCE a Good Investment? Thesis Analysis
NeuroPace demonstrates strong revenue growth of 25.1% YoY and exceptional gross margins of 77.2%, indicating solid product demand and pricing power. However, the company is burning cash with negative operating cash flow of -$11.0M, negative net income of -$21.5M, and a concerning debt-to-equity ratio of 3.09x, raising sustainability questions despite $21.7M in cash reserves.
Why Buy NPCE? Key Strengths
- Revenue growth of 25.1% YoY demonstrates strong market traction in neurostimulation devices
- Gross margin of 77.2% indicates excellent pricing power and manufacturing efficiency
- Strong liquidity position with current ratio of 5.28x and $21.7M cash provides near-term operational flexibility
NPCE Investment Risks to Consider
- Company is unprofitable with negative operating income (-$16.3M) and net income (-$21.5M) despite 25.1% revenue growth
- Negative operating cash flow of -$11.0M indicates inability to self-fund operations; cash burn rate unsustainable long-term
- High leverage with debt-to-equity of 3.09x and $58.9M long-term debt relative to $19.0M stockholders equity creates financial fragility
Key Metrics to Watch
- Path to operating profitability and timeline for positive operating cash flow
- Debt reduction strategy and long-term debt management relative to growing revenue base
- Cash runway and monthly burn rate to assess sustainability without additional capital raises
NPCE Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.28x current ratio provides a solid financial cushion.
NPCE Profitability Ratios
NPCE vs Healthcare Sector
How NeuroPace Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NPCE Overvalued or Undervalued?
Based on fundamental analysis, NeuroPace Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NPCE Balance Sheet & Liquidity
NPCE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NeuroPace Inc's revenue has grown significantly by 121% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.93 indicates the company is currently unprofitable.
NPCE Growth Metrics (YoY)
NPCE Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $21.1M | -$3.5M | $-0.11 |
| Q2 2025 | $19.3M | -$6.6M | $-0.26 |
| Q1 2025 | $18.1M | -$6.6M | $-0.21 |
| Q3 2024 | $16.4M | -$5.5M | $-0.19 |
| Q2 2024 | $16.5M | -$7.5M | $-0.26 |
| Q1 2024 | $14.5M | -$8.9M | $-0.32 |
| Q3 2023 | $11.2M | -$7.3M | $-0.28 |
| Q2 2023 | $10.2M | -$9.1M | $-0.36 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NPCE Capital Allocation
NPCE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NeuroPace Inc (CIK: 0001528287)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 25, 2026 | 4 | xslF345X06/wk-form4_1774470047.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774385234.xml | View → |
| Mar 24, 2026 | 4 | xslF345X06/wk-form4_1774385141.xml | View → |
| Mar 23, 2026 | 4 | xslF345X06/wk-form4_1774298557.xml | View → |
| Mar 23, 2026 | 4 | xslF345X06/wk-form4_1774298494.xml | View → |
❓ Frequently Asked Questions about NPCE
What is the AI rating for NPCE?
NeuroPace Inc (NPCE) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NPCE's key strengths?
Claude: Revenue growth of 25.1% YoY demonstrates strong market traction in neurostimulation devices. Gross margin of 77.2% indicates excellent pricing power and manufacturing efficiency.
What are the risks of investing in NPCE?
Claude: Company is unprofitable with negative operating income (-$16.3M) and net income (-$21.5M) despite 25.1% revenue growth. Negative operating cash flow of -$11.0M indicates inability to self-fund operations; cash burn rate unsustainable long-term.
What is NPCE's revenue and growth?
NeuroPace Inc reported revenue of $100.0M.
Does NPCE pay dividends?
NeuroPace Inc does not currently pay dividends.
Where can I find NPCE SEC filings?
Official SEC filings for NeuroPace Inc (CIK: 0001528287) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NPCE's EPS?
NeuroPace Inc has a diluted EPS of $-0.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NPCE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NeuroPace Inc has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NPCE stock overvalued or undervalued?
Valuation metrics for NPCE: ROE of -112.8% (sector avg: 15%), net margin of -21.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NPCE stock in 2026?
Our dual AI analysis gives NeuroPace Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NPCE's free cash flow?
NeuroPace Inc's operating cash flow is $-11.0M, with capital expenditures of $332.0K. FCF margin is -11.3%.
How does NPCE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -21.5% (avg: 12%), ROE -112.8% (avg: 15%), current ratio 5.28 (avg: 2).